Viagra's First Act: The Vascular Drug It Was Always Meant to Be
Sildenafil was built to be a heart drug — the effect it's famous for was the accident. The evidence now ties it to the earliest stage of heart disease, the aging brain, and lower cancer risk.
William H. Light, MD
8/8/20262 min read
Most people file the PDE5 inhibitors — sildenafil (Viagra) and tadalafil (Cialis) — under one heading, and it's the wrong one. This was never a sex drug that wandered into cardiology. Sildenafil was designed as a cardiovascular drug: the goal was to dilate the coronary arteries and lower blood pressure. The erectile effect was the surprise — the real "second act." Treating the vascular system was the first, and it was the whole point.
The mechanism ties a whole philosophy of longevity together. These drugs prolong nitric-oxide signaling — nitric oxide being the master molecule of vascular health, the one that keeps the endothelium, the living lining of every artery you own, working properly. Endothelial dysfunction is the first step in atherosclerosis, appearing years before plaque. A drug that supports that system is acting on the earliest stage of the disease that kills more people than anything else.
There's a clinical pearl here every man over 40 should know: an erection is a vascular event, and the penile arteries are small. New erectile dysfunction after 40 can precede a heart attack by three to five years. A good internist treats it as a cardiovascular finding, not just a quality-of-life one.
The same logic always ran upward, to the brain. A drug that relaxes and widens arteries should widen the ones feeding the brain too, and better cerebral perfusion was expected to help wash out tau and the other metabolic debris that builds up with age. That idea was on the table long before the glymphatic system — the brain's overnight rinse cycle — had even been described. The old vascular intuition and the new anatomy point the same direction, and the population data have begun to follow: PDE5 use tracks with lower rates of dementia. The trial-grade proof isn't in, but the arrow is consistent.
And then the newest twist. In 2026, researchers at the Weizmann Institute published a genuinely novel mechanism in Cancer Research: the same rise in cyclic GMP that these drugs produce traps cholesterol inside the lysosome of cancer cells — starving them of the raw material they need to spread. It dovetails with human genetic evidence suggesting PDE5 inhibition is associated with markedly lower colorectal and gastric cancer risk, with no increased risk across the board. The old melanoma scare, meanwhile, appears to be confounding, not cause.
The honest bottom line: none of this is a reason to self-prescribe, and the trial-grade proof isn't all in. But a cheap, generic, decades-old pill that was built for the heart, works on the earliest stage of heart disease, and may make the body a harder place for cancer to spread — while the brain data quietly accumulate — is a remarkable story. It's a near-perfect example of this book's thesis that the field keeps rewarding the boring old drugs.
Adapted from Outlast by William H. Light, MD. Talk to your physician — this is a real drug with real interactions, including a dangerous one with nitrates.